In this episode, guests Fatima Stanford, MD, MPH, and Philip Mease, MD, discuss the role of GLP-1s in inflammatory diseases, determining who and how these medications should be prescribed and more.

· Intro 0:28

· Fatima C. Stanford, MD, MPH, MPA, MBA, MACP, FAAP, FAHA, FAMWA, FTOS, and Philip J. Mease, MD 0:37

· Fatima, from your expert perspective, how did we get here with GLP-1 usage, and where is the field going? 1:12

· Have these medications reached their maximum benefit for patients or are we going to see GLP-1 agonists improve? 2:30

· Philip, as a rheumatologist, can you tell us how you think about GLP-1 medications and obesity in general when approaching a rheumatic patient? 4:09

· Fatima, what are the best ways to approach the subject of obesity with patients? 7:46

· Philip, when do you broach the topic of how GLP-1s will impact patients with rheumatic disease? 11:09

· Which rheumatic diseases are most amenable to being improved by weight loss, GLP-1 agonism or a combination of both? 14:27

· Where do you see GLP-1s role in improving inflammatory diseases? 16:29

· Philip, what is your take on rheumatologists prescribing these medications directly? 18:43

· Fatima, what should those who are not experts in GLP-1 usage know about how prescribe these medications and help patients be successful on them? 21:23

· Are there serious side effects we need to worry about? 24:57

· Are there things you check before starting someone on a GLP-1 medication, or monitor while they are on one? 26:24

· Discussion on advisements on when to be NPO in preparation for surgery while taking these medications. 28:00

· Final thoughts: Where do you see the future going in this field of medicine? 29:46

· Thanks for listening. 32:39

Fatima C. Stanford, MD, MPH, MPA, MBA, MACP, FAAP, FAHA, FAMWA, FTOS, is an obesity medicine physician scientist at Massachusetts General Hospital and Harvard Medical School. Philip J. Mease, MD, is director of rheumatology research at Swedish Medical Center/Providence St. Joseph Health and a clinical professor at the University of Washington School of Medicine in Seattle. We’d love to hear from you! Send your comments/questions to Dr. Gelfand at [email protected]. Follow Dr. Gelfand on LinkedIn. For more, be sure to visit the Beneath the Surface video blog on Healio.com. Disclosures: Gelfand is Chief Medical Editor of Healio Dermatology. Mease reports receiving research grants, consultant fees and/or speaker honoraria from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Century, Cullinan, Eli Lilly, Immagene, Janssen, Moonlake Pharma, Novartis, Pfizer, Spyre, Takeda and UCB. Stanford reports consulting for Boehringer Ingelheim, Currax, Eli Lilly, Gelesis, Novo Nordisk, Pfizer and Rhythm Pharmaceuticals and serving on advisory boards for Eli Lilly and Novo Nordisk.